Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

FDA's NDA And BLA Approvals: Kisqali, Voriconazole
US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say
Blood Cancer Sector More Competitive After Keytruda Approval
Opana ER Looking At REMS – Or Worse – After US FDA Panel Weighs Intravenous Abuse Risk
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter
Buying ZS Pharma Could Give AstraZeneca Best-In-Class Blockbuster

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel